Singapore, July 29 -- AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group, has announced that construction of its new R&D building has officially broken ground at the Shanghai Fengxian site.

The project marks a pivotal infrastructure step in strengthening AsymBio's biologics CDMO capabilities and reinforcing the Fengxian site's role as a core development-and-manufacturing hub.

Construction began in May 2026, with full completion and official commissioning slated for the second half of 2027. The eight-story building will occupy approximately 2,500 square meters of land, provide nearly 20,000 square meters of gross floor area, and be constructed in full compliance with...